Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ling Ni

Showing results (211-220 of 215) with videos related to

Pageof 22
Sort By:
You have reached the last page of results.This site can display upto 215 results.
Human Vaccines & Immunotherapeutics|October 26, 2023
Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trialGuang-Wei Feng, Zhong-Fang Wang, Peng He, et al.
Science Bulletin|February 27, 2026
The role of artificial intelligence in advancing population-based cancer registrationShuai Ding, Mingyuan Liu, Hao Wang, et al.
The Journal of Molecular Diagnostics : JMD|August 13, 2022
Sequential Approach to Improve the Molecular Classification of Childhood Acute Lymphoblastic LeukemiaChih-Hsiang Yu, Gang Wu, Chia-Ching Chang, et al.
The Lancet. Microbe|January 31, 2022
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trialGui-Ling Chen, Xiao-Feng Li, Xia-Hong Dai, et al.
Cancer|December 20, 2022
Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemiaChih-Hsiang Yu, Shiann-Tarng Jou, Ying-Hui Su, et al.
Pageof 22

Showing results (211-220 of 215) with videos related to

Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 215 results.
Human Vaccines & Immunotherapeutics|October 26, 2023
Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trialGuang-Wei Feng, Zhong-Fang Wang, Peng He, et al.
Science Bulletin|February 27, 2026
The role of artificial intelligence in advancing population-based cancer registrationShuai Ding, Mingyuan Liu, Hao Wang, et al.
The Journal of Molecular Diagnostics : JMD|August 13, 2022
Sequential Approach to Improve the Molecular Classification of Childhood Acute Lymphoblastic LeukemiaChih-Hsiang Yu, Gang Wu, Chia-Ching Chang, et al.
The Lancet. Microbe|January 31, 2022
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trialGui-Ling Chen, Xiao-Feng Li, Xia-Hong Dai, et al.
Cancer|December 20, 2022
Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemiaChih-Hsiang Yu, Shiann-Tarng Jou, Ying-Hui Su, et al.
Pageof 22